2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥149,723,992.40, representing a 92.93% increase compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was -¥143,600,577.66, a decrease of 70.49% year-on-year[4]. - Year-to-date net profit attributable to shareholders reached -¥985,029,654.47, showing a significant increase of 107.63% compared to the same period last year[4]. - The company's operating revenue for the current reporting period increased by 92.93%, primarily due to a significant rise in sales of meningococcal vaccines compared to the same period last year[25]. - Year-to-date operating revenue decreased by 75.17%, mainly due to a substantial decline in sales of COVID-19 vaccines, which had a large contribution in the previous year[25]. - The net profit attributable to shareholders for the current reporting period showed a decrease of 70.49%, reflecting a net loss for the period[25]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 64.54% in the current reporting period[25]. - The company reported a net loss of approximately ¥1,454.92 million for the current period, compared to a net loss of ¥488.68 million in the previous period, indicating a significant decline in profitability[35]. - The company’s total profit for the current period was approximately -¥1,456.08 million, compared to -¥646.85 million in the previous period, indicating a significant increase in losses[34]. - The comprehensive income total for the third quarter of 2023 was -CNY 1,454,797,112.46, a significant decline from -CNY 488,625,829.08 in the same quarter of 2022[51]. Research and Development - Research and development expenses totaled ¥140,476,879.33 in Q3 2023, a decrease of 38.80% year-on-year[23]. - Research and development expenses for the current reporting period decreased by 38.80%, as the focus shifted away from COVID-19 vaccine-related R&D[25]. - The ratio of R&D expenses to operating revenue was 93.82%, a decrease of 201.94 percentage points compared to the previous year[23]. - The ratio of R&D expenses to operating revenue decreased by 201.94 percentage points in the current reporting period[25]. - Research and development expenses decreased to approximately ¥461.67 million from ¥549.07 million, showing a reduction in investment in R&D[34]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥9,610,642,425.30, down 19.34% from the end of the previous year[23]. - The equity attributable to shareholders was ¥5,770,626,650.09, a decrease of 16.94% compared to the previous year[23]. - The total liabilities amounted to ¥3,812,394,223.51, down from ¥4,223,356,561.52 in the previous year[18]. - The total assets as of September 30, 2023, amounted to approximately CNY 9.61 billion[31]. - The total liabilities as of September 30, 2023, were approximately CNY 2.47 billion[31]. - Total current assets decreased to CNY 5,527,055,428.52 as of September 30, 2023, from CNY 7,730,184,538.12 at the end of 2022[43]. - Inventory as of September 30, 2023, was CNY 417,379,697.15, a decrease from CNY 677,776,961.91 at the end of 2022[43]. - Non-current assets increased to CNY 2,873,570,857.79 as of September 30, 2023, from CNY 2,891,316,509.78 at the end of 2022[43]. Cash Flow - The net cash flow from operating activities was -¥748,974,021.75, reflecting a 46.24% decline compared to the previous year[23]. - The company recorded a net cash outflow from operating activities of approximately -¥748.97 million, an improvement from -¥1,393.28 million in the previous period[39]. - Cash and cash equivalents at the end of the period totaled approximately ¥2,350.99 million, down from ¥2,964.82 million at the end of the previous period[40]. - The company's cash and cash equivalents as of September 30, 2023, were CNY 3,221,172,324.19, down from CNY 3,464,734,156.87 at the end of 2022[43]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 615,809,046.71, down from CNY 763,592,237.08 in the same period of 2022[52]. - Cash received from sales of goods and services in the first three quarters of 2023 was CNY 311,333,825.97, compared to CNY 374,158,061.76 in the same period of 2022[52]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,196[26]. - The largest shareholder, HKSCC NOMINEES LIMITED, held 39.63% of the shares[26]. - Basic and diluted earnings per share for the third quarter of 2023 were both -CNY 3.99, compared to -CNY 1.92 in the same quarter of 2022[51].